Adaptimmune Therapeutics Plc ADR (NASDAQ: ADAP) on Tuesday, soared 1.35% from the previous trading day, before settling in for the closing price of $0.59. Within the past 52 weeks, ADAP’s price has moved between $0.43 and $2.05.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 134.88% over the past five years. The company achieved an average annual earnings per share of 71.06%. With a float of $226.49 million, this company’s outstanding shares have now reached $255.70 million.
Let’s look at the performance matrix of the company that is accounted for 449 employees. In terms of profitability, gross margin is 95.26%, operating margin of -28.14%, and the pretax margin is -28.42%.
Adaptimmune Therapeutics Plc ADR (ADAP) Insider Updates
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Adaptimmune Therapeutics Plc ADR is 11.49%, while institutional ownership is 42.01%. The most recent insider transaction that took place on Jun 18 ’24, was worth 22,814. In this transaction Chief Commercial Officer of this company sold 24,531 shares at a rate of $0.93, taking the stock ownership to the 38,293 shares. Before that another transaction happened on Jan 17 ’24, when Company’s Chief Executive Officer sold 30,080 for $0.67, making the entire transaction worth $20,244. This insider now owns 44,848 shares in total.
Adaptimmune Therapeutics Plc ADR (ADAP) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around 71.06% per share during the next fiscal year.
Adaptimmune Therapeutics Plc ADR (NASDAQ: ADAP) Trading Performance Indicators
Adaptimmune Therapeutics Plc ADR (ADAP) is currently performing well based on its current performance indicators. A quick ratio of 3.82 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 0.87.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.21, a number that is poised to hit -0.03 in the next quarter and is forecasted to reach -0.08 in one year’s time.
Technical Analysis of Adaptimmune Therapeutics Plc ADR (ADAP)
Adaptimmune Therapeutics Plc ADR (NASDAQ: ADAP) saw its 5-day average volume 2.32 million, a positive change from its year-to-date volume of 1.75 million. As of the previous 9 days, the stock’s Stochastic %D was 21.32%. Additionally, its Average True Range was 0.05.
During the past 100 days, Adaptimmune Therapeutics Plc ADR’s (ADAP) raw stochastic average was set at 5.20%, which indicates a significant decrease from 25.57% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 54.87% in the past 14 days, which was lower than the 80.58% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.7371, while its 200-day Moving Average is $1.0525. Nevertheless, the first resistance level for the watch stands at $0.6184 in the near term. At $0.6375, the stock is likely to face the second major resistance level. The third major resistance level sits at $0.6616. If the price goes on to break the first support level at $0.5752, it is likely to go to the next support level at $0.5511. Assuming the price breaks the second support level, the third support level stands at $0.5320.
Adaptimmune Therapeutics Plc ADR (NASDAQ: ADAP) Key Stats
Market capitalization of the company is 153.37 million based on 255,883K outstanding shares. Right now, sales total 60,280 K and income totals -113,870 K. The company made 40,900 K in profit during its latest quarter, and -17,620 K in sales during its previous quarter.
